Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a...
Q2 2026
Aug 12, 2026
Q1 2026
May 11, 2026
FY 2025
Mar 16, 2026
Q4 2025
Q3 2025
Nov 10, 2025